Bank of New York Mellon Corp Sells 23,233 Shares of DaVita Inc. $DVA

Bank of New York Mellon Corp reduced its position in shares of DaVita Inc. (NYSE:DVA) by 6.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 353,061 shares of the company’s stock after selling 23,233 shares during the period. Bank of New York Mellon Corp’s holdings in DaVita were worth $50,294,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Invesco Ltd. increased its stake in DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after buying an additional 53,402 shares during the last quarter. Northern Trust Corp increased its position in shares of DaVita by 20.2% during the first quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after acquiring an additional 149,858 shares during the last quarter. Gates Capital Management Inc. lifted its holdings in DaVita by 0.7% during the first quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock worth $110,476,000 after acquiring an additional 4,698 shares during the period. Amundi boosted its position in DaVita by 16.0% in the first quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after purchasing an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. grew its stake in DaVita by 10.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock valued at $62,400,000 after purchasing an additional 39,485 shares during the period. 90.12% of the stock is owned by institutional investors.

DaVita Trading Up 1.7%

DaVita stock opened at $122.27 on Wednesday. The firm has a 50 day simple moving average of $128.50 and a 200 day simple moving average of $135.72. DaVita Inc. has a 1-year low of $115.39 and a 1-year high of $179.60. The firm has a market capitalization of $8.63 billion, a price-to-earnings ratio of 12.59, a P/E/G ratio of 0.91 and a beta of 1.13.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.43 billion. DaVita had a return on equity of 815.62% and a net margin of 5.80%.DaVita’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on DVA. Barclays lowered their target price on DaVita from $149.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Thursday, October 30th. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Cowen restated a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Finally, Zacks Research lowered DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average price target of $148.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.